Recent aspects of physiological features and effects of renal dopamine;Novije spoznaje o fiziološkim svojstvima i učincima bubrežnog dopamina

Lijecnicki Vjesnik

Volumn 126, Issue 5-6, 2004, Pages 147-155

  Ćuk, Mira ^a   Ćuk, Duro ^b   Dvornik, Štefica ^b   Mamula, Ozren ^b   Matanič Manestar, Marija ^b  

^a UNIVERSITY OF RIJEKA   (Croatia)

^b KBC RIJEKA   (Croatia)

Author keywords

Blood pressure; Dopamine physiology; Kidney physiology; Natriuresis; Receptors, dopamine physiology; Signal transduction

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADENYLATE CYCLASE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE 4 RECEPTOR; DOPAMINE 5 RECEPTOR; GUANINE NUCLEOTIDE BINDING PROTEIN; SODIUM PROTON EXCHANGE PROTEIN;

AUTOCRINE EFFECT; BASOLATERAL MEMBRANE; BLOOD PRESSURE REGULATION; ELECTROLYTE BALANCE; ENZYME INHIBITION; ESSENTIAL HYPERTENSION; FLUID BALANCE; HEREDITARY HYPERTENSION; HORMONE ACTION; HORMONE SYNTHESIS; KIDNEY BLOOD FLOW; KIDNEY FUNCTION; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE CELL; NEUROTRANSMISSION; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; SODIUM RETENTION; ANIMAL; HUMAN; KIDNEY; METABOLISM; PHYSIOLOGY;

ANIMALS; DOPAMINE; HUMANS; KIDNEY;

EID: 9144259587     PISSN: 00243477     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (93)

1. Saper CB. Brain stem modulation of sensation, movement, and consciousness. U: Kandel ER, Schwartz JH, Jessell TM, ur. Principles of neural science. New York: McGraw-Hill 2000, str. 889-909.
2. Kuhar MJ, Conceyro PR, Lambert PD. Catecholamines. U: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD, ur. Basic neurochemistry - molecular, cellular and medical aspects. Philadelphia: Lippincott Williams & Wilkins 1999, str. 242-261.
3. Austin L, Livett BG, Chubb IW. Increased synthesis and release of noradrenaline and dopamine during nerve stimulation. Life Sci 1967;6:97-104.
4. Neff NH, Karoum F, Hadjiconstantinou M. Dopamine-containing small intensely fluorescent cells and sympathetic ganglion function. Federation Proc 1983;42:3009-3011.
5. Lacković Z, Neff NH. Evidence that dopamine is a neurotransmitter in peripheral tissues. Life Sci 1983;32:1665-74.
6. Stokes AH, Hastings TG, Vrana KE. Cytotoxic and genotoxic potential of dopamine. J Neurosci Res 1999;55(6):659-65.
7. Duncan GE, Sheitman BB, Lieberman JA. An integrated view of pathophysiological models of schizophrenia. Brain Res Brain Res Rev 1999;29(2-3):250-64.
8. Jankovic J. Tourette's syndrome. N Engl J Med 2001;345(16):1184-92.
9. Ben-Jonathan N, Hnasko R. Dopamine as a prolactin (PRL) inhibitor. Endocr Rev 2001;22(6):724-63.
10. Lee MR. Dopamine and the kidney. Clin Sci (Lond) 1982;62(5):439-48.
11. Goldstein DS. Novel catecholaminergic systems. Adv Pharmacol 1998;42:819-24.
12. Holtback U, Kruse MS, Brismar H, Aperia A. Intrarenal dopamine coordinates the effect of antinatriuretic and natriuretic factors. Acta Physiol Scand 2000;168(1):215-8.
13. Carey MR. Renal dopamine system - paracrine regulator of sodium homeostasis and blood pressure. Hypertension 2001;38:297-302.
14. Jose PA, Eisner GM, Felder RA. Role of dopamine receptors in the kidney in the regulation of blood pressure. Curr Opin Nephrol Hypertens 2002;11:87-92.
15. Vaugham CJ, Aherne AM, Lane E, Power O, Carey RM, O'Connell DP. Identification and regional distribution of the D-1A receptor in the gastrointestinal tract. Am J Physiol Regul Integr Comp Physiol 2000;279(2): R599-R609.
16. Hussain T, Lokhandwala MF. Renal dopamine receptor function in hypertension. Hypertension 1998;32:187-97.
17. Kuchel O. Peripheral dopamine in hypertension and associated conditions. J Hum Hypertens 1999;13(9):605-15.
18. O'Conell DP, Aherne AM. Renal dopaminergic mechanisms and hypertension: a chronology of advances. Clin Exp Hypertens 2000;22(3):217-49.
19. Ferreira A, Bettencourt P, Pestana M i sur. Heart failure, aging, and renal synthesis of dopamine. Am J Kidney Dis 2001;38(3):502-9.
20. Contreras F, Fouillioux C, Bolivar A i sur. Dopamine, hypertension and obesity. J Hum Hypertens 2002;16(Suppl 1):S13-7.
21. Aperia AC. Intrarenal dopamine: a key signal in the interactive regulation of sodium metabolism. Annu Rev Physiol 2000;62:621-47.
22. Jose PA, Eisner GM, Felder RA. Dopamine and the kidney: a role in hypertension? Curr Opin Nephrol Hypertens 2003;12(2):189-94.
23. Eldrup E, Richter EA, Hetland ML isur. Origin and significance of plasma dihydroxyphenylalanine. Adv Pharmacol 1998;42:851-4.
24. Landsberg L, Young JB. Physiology and pharmacology of autonomic nervous system (68). U: Isselbaeher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL eds. Harrison'sPrinciples of internal medicine. New York McGraw Hill 1997, str. 360-371.
25. Takezako T, Noda K, Tsuji E, Koga M, Sasaguri M, Arakawa K. Adenosine activates aromatic L-amino acid decarboxylase activity in the kidney and increases dopamine. J Am Soc Nephrol 2001;12(1):29-36.
26. Aguire JA, Ibarra FR, Barontini M, Arrizuieta EE, Armando I. Effect of glucocorticoids on renal dopamine production. Eur J Pharmacol 1999;370 (3):271-8.
27. Del Compare JA, Aguirre JA, Ibarra FR, Barontini M, Armando I. Effects of thyroid hormone on the renal dopaminergic system. Endocrine 2001;15 (3):297-303.
28. Barendreght JNM, Pannerden LLAMV, Chang PC. Modulation of natriuresis and renal dopamine excretion by sympathetic activity and the renin-angiotensin- aldosterone system. J Hum Hypertens 1994;8(10):747-54.
29. Wang ZQ, Siragy HM, Felder RA, Carey RM. Intrarenal dopamine production and distribution in the rat - physiological control of sodium excretion. Hypertension 1997;29(1 part 2):228-34.
30. Carranza A, Karabatas L, Barontini M, Armando I. Decreased tubular uptake of L-3,4,-dihydroxyphenylalanine in streptozotocin-induced diabetic rats. Horm Res 2001;55(6):282-7.
31. Soares-da-Silva P, Viera-Coelho MA. Nonneuronal dopamine. Adv Pharmacol 1998;42:866-9.
32. Yoshimura M, Komori T, Nishimura M i sur. Diagnostic significance of dopamine estimation using plasma and urine in patients with adrenal and renal insufficiency, renal transplantation and hypertension. Hypertens Res 1995;18(Suppl 1):S87-92.
33. Hayashi M, Shimamoto K, Tsuchihashi K i sur. Role of renal dopaminergic activity on renal sodium-water metabolism in congestive heart failure. Clin Exp Pharmacol Physiol 1996;23(10-11):874-7.
34. Eisenhofer G. The role of neuronal and extraneuronal plasma membrane transporters in the inactivation of peripheral catecholamines. Pharmacol Ther 2001;91(1):35-62.
35. Van Loon GR. Plasma dopamine: regulation and significance. Federation Proc 1983;42:3012-8.
36. Boulton AA, Eisenhofer G. Catecholamine metabolism - from molecular understanding to clinical diagnosis and treatment. Adv Pharmacol 1998;42:273-92.
37. Zabetian CP, Anderson GM, Buxbaum SG i sur. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity; evidence for a major functional polymorphism at the DBH locus. Am J Hum Genet 2001;68(2):515-22.
38. Eisenhofer G, Coughtrie MW, Goldstein DS. Dopamine sulphate: an enigma resolved. Clin Exp Pharmacol Physiol 1999;Suppl 26:541-53.
39. Musso NR, Gianrossi R, Pende A, Vergassola C, Lotti G. Plasma dopamine response to sympathetic activation in man: a biphasic pattern. Life Sci 1990;47:619-26.
40. Miura Y, Watanabe T, Noshiro T i sur. Plasma free dopamine: physiological variability and pathophysiological significance. Hypertens Res 1995;18(Suppl 1):S65-72.
41. Snider SR, Kuchel O. Dopamine: an important neurohormone of the sympathoadrenal system. Significance of increased peripheral dopamine release for the human stress response and hypertension. Endocr Rev 1983;4 (3):291-309.
42. Olsen NV: Effects of dopamine on renal haemodynamics. tubular function and sodium excretion in normal humans. Dan Med Bull 1998;45(3): 282-97.
43. Amenta F, Ricci A, Rossodivita I, Avola R, Taybati SK. The dopaminergic system in hypertension. Clin Exp Hypertens 2001;23(1-2):15-24.
44. Bek MJ, Eisner GM. Dopamine receptors in the hypertension. Mt Sinai J Med 2001;68(6):362-9.
45. Amenta F, Ricci A, Tayebati SK, Zaccheo D. The peripheral dopaminergic system: morphological analysis, functional and clinical applications. Ital J Anat Embryol 2002;107(3):145-67.
46. Kellum JA, Janine M, Decker RN. Use of dopamine in acute renal failure: A meta-analysis. Crit Care Med 2001:29(8):1526-31.
47. Hussain T, Lokhandwala MF. Renal dopamine receptors and hypertension. Exp Biol Med 2003;228(2):134-42.
48. Yamaguchi I, Yao L, Sanada H i sur. Dopamine D-1A receptors and renin release in rat juxtaglomerular cells. Hypertension 1997;29(4):962-8.
49. Stamler SJ, Dzau VJ, Loscalzo J. The vascular smooth muscle cell (3). U: Loscalzo J, Creager MA, Dzau VJ, ur. Vascular medicine. Boston: Little, Brown and Company, 1992. str. 69-116.
50. Ozono R, O'Connell DP, Wang ZQ i sur. Localization of the dopamine D1 receptor protein in the human heart and kidney. Hypertension 1997;30(3 Pt 2):725-9.
51. Ogawa N. Molecular and chemical neuropharmacology of dopamine receptor subtypes. Acta Med Okayama 1995;49(1):1-11.
52. Aperia A, Eklof AC, Holtback U, Nawicki S, Sundelof M, Greengard P. The renal dopamine system. Adv Pharmacol 1998;42:870-3.
53. Zheng S, Yu P, Zeng C i sur. G alpha(12)- and G alpha(13)-protein subunit linkage of D-5 dopamine receptors in the nephron. Hypertension 2003;41(3):604-10.
54. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, ur. Molecular biology of the cell. New York: Garland Science; 2002, str. 831-906.
55. +ATPase: a final common pathway for regulation of natriuresis. FASEB J 1994;8:436-9.
56. Nowicki S, Kruse MS, Brismar H, Aperia A. Dopamine-induced translocation of protein kinase C isoforms visualized in renal epithelial cells. Am J Physiol Cell Physiol 2000;279(6):C1812-C1818.
57. Maier KG, Roman RJ. Cytochrome P450 metabolites of arachidonic acid in the control of renal function. Curr Opin Nephrol Hypertens 2001;10(1): 81-87.
58. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001;53(1):1-24.
59. Watanabe H, Xu J, Bengra C, Jose PA, Felder RA. Desensitization of human renal D-1 dopamine receptors by G protein-coupled receptor kinase 4. Kidney Int 2002;62(3):790-8.
60. Murphy MB, Murray C, Shorten GD. Drug therapy: Fenoldopam - a selective peripheral dopamine - receptor agonist for the treatment of severe hypertension. New Engl J Med 2001;435(21):1548-57.
61. Velasco M, Luchsinger A. Dopamine: pharmacologic and therapeutic aspects. Am J Ther 1998;5(1):37-43.
62. Weiss B, Zhang SP, Zhou LW. Antisense strategies in dopamine receptor pharmacology. Life Sci 1997;60(7):433-55.
63. Jose PA, Eisner GM, Felder RA. Dopamine receptor-coupling defect in hypertension. Curr Hypertens Rep 2002;4(3):237-44.
64. Umrani DN, Banday AA, Hussain T, Lokhandwala MF. Rosiglitazone treatment restores renal dopamine receptor function in obese Zucher rats. Hypertension 2002;40(6):880-5.
65. Shin Y, Kumar U, Patel Y, Patel SC, Sidhu A. Different expression of D-2-like dopamine receptors in the kidney of the spontaneously hypertensive rat. J Hypertens 2003;21(1):199-207.
66. Strange PE. Agonism and inverse agonism at dopamine D-2-like receptors. Clin Exp Pharmacol Physiol 1999;26(Suppl S):S3-S9.
67. Doggrell SA. The terapeutic potential of dopamine modulators on the cardiovascular and renal systems. Expert Opin Investig Drugs 2002;11(5): 631-44.
68. Bailey JM. Dopamine - one size does not fit all. Anesthesiology 1999;92 (2):303-5.
69. Taylor TB, Cockrill BA. Renal-dose dopamine: a siren song? Lancet 1994;344(8914):7-8.
70. MacGregor DA, Smith TE, Prelipp RC, Butterworth JF, James RL, Scuderi PE. Pharmacokinetics of dopamine in healthy male subjects. Anesthesiology 2000;92(2):338-46.
71. Power DA, Duggan J, Brady HR. Renal-dose (low-dose) dopamine for the treatment of sepsis-related and other forms of acute renal failure: ineffective and probably dangerous. Clin Exp Pharmacol Physiol 1999; Suppl 26:523-8.
72. Laville M. Review: low-dose dopamine does not prevent acute renal failure or reduce mortality or need for hemodialysis. ACP J Club 2002;136(1):p3.
73. Murphy MB. Dopamine: a role in the pathogenesis and treatment of hypertension. J Hum Hypertens 2000;14(Suppl 1):S47-50.
74. Yasunari K, Kohno M, Kano H, Hanehira T, Minami M, Yoshikawa J. Anti-atherosclerotic action of vascular D1 receptors. Clin Exp Pharmacol Physiol 1999;(Suppl 26):S36-40.
75. Ganguly PK, Mukherjee K, Sahai A. Renal dopamine receptors are involved in the development of cardiac hypertrophy. Mol Cell Biochem 1995;144(1):81-4.
76. Greger R. Physiology of renal sodium transport. Am J Med Sci 2000;319(1):51-62.
77. +ATPaSe. Annu Rev Biochem 2002;71: 511-35.
78. Aperia A. Regulation of sodium/potassium ATPase activity: impaired salt balance and vascular contractility. Curr Hypertens Rep 2001;3(2): 165-71.
79. Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P, ur. Molecular biology of the cell. New York: Garland Science; 2002, str. 615-57.
80. Barendreght JNM, Muizert Y, Pannerden LLAMVT, Chang PC. Intrarenal production of dopamine and natriuresis following DOPA and saline infusions in healthy human volunteers. J Hum Hypertens 1995;9(3):187-94.
81. Zeng C, Peiying Y, Asico LD, Hopfer U, Eisner GM, Jose PA. D3 dopamine receptor up regulates and directly interacts with the D1 dopamine receptor in renal proximal tubular cells. Am J Hypertens 2002;15(4)(Suppl 1):pA11.
82. Strazzullo P, Galetti F, Barba G. Altered renal handling of sodium in human hypertension. Short review of the evidence. Hypertension 2003;41:1000.
83. Williams GH. Arterial hypertension (209). U: Isselbacher KJ, Braunwald E, Wilson JD, Martin JB, Fauci AS, Kasper DL eds. Harrison's Principles of internal medicine. New York McGraw Hill 1997, str. 973-85.
84. Ogowo Y, Itoh H, Nakao K. Molecular biology and biochemistry of natriuretic peptide family. Clin Exp Pharmacol Physiol 1995;22:49-53.
85. Soares da Silva P, Vieira Coelho MA, Pinto do O PC, Pestana M, Bertorello AM. Studies on the nature of the antagonistic actions of dopamine and 5-hydroxytryptamine in renal tissues. Hypertens Res 1995;18(Suppl 1): S47-51.
86. +. Br J Pharmacol 2002;137 (8):1380-6.
87. Cheng HF, Becker BN, Harris RC. Dopamine decreases expression of type-1 angiotensin II receptors in renal proximal tubule. J Clin Invest 1996;97(12):2745-52.
88. Zeng CY, Asico LD, Wang XL i sur. Angiotensin II regulation of AT(1) and D-3 dopamine receptors in renal proximal tubule cells of SHR. Hypertension 2003;41(3 Part 2):724-9.
89. + exchanger interactions in the kidney in hypertension. Hypertension 2000;36(3):395-9.
90. + exchanger (NHE3) endocytosis via clatrin-coated vesicles. J Biol Chem 2001;276(29):26906-15.
91. + exchanger gene family. J Nephrol 2002;15(5):S3-21.
92. Murer H, Hernando N, Forster I, Biber J. Proximal tubular phosphate reabsorption, molecular mechanisms. Physiol Rev 2000;80(4):1373-409.
93. Blaustein MP, Lederer WJ. Sodium/calcium excange: its physiological implications. Physiol Rev 1999;79(3):763-854.